Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy

Stem Cells Arabia50 enrolled

Overview

This study is a single arm, single center trial to study the safety and efficacy of purified autologous bone marrow derived stem cells and mesenchymal stem cells for the treatment of children with cerebral palsy.

Cerebral palsy (CP) is a chronic childhood disorder defined by a range of motor and cognitive impairments and results in a substantial suffering to the patient and a tremendous socio-economic burden to the individual, family, and healthcare system. With no effective treatments or interventions, therapies for CP are currently focused on supportive and management strategies. Stem cell transplantation has been suggested as a putative intervention for neural pathology, as mesenchymal and neural stem cells, as well as olfactory ensheathing glia and Schwann cells, which have shown some regenerative and functional efficacy in experimental central nervous system disorders. In this trial, the investigators study the safety and efficacy of the intrathecal transplantation of specific populations of purified autologous bone marrow-derived stem cells and mesenchymal stem cells in patients with cerebral palsy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cerebral Palsy

Interventions

Stem Cell TherapyBIOLOGICAL

Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.

Eligibility

Sex: ALLMin age: 2 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must be more than 2 year of age and less than 12 years of age at the time of screening for inclusion in the study. * Clinical evidence of a non-progressive motor disability due to brain dysfunction. * Willing to comply with all study procedures. * Gross Motor Function Classification Score level II-V Exclusion Criteria: Known history of: * Intractable seizures * Traumatic brain injury * Genetic disorder * Current Infection * Renal insufficiency * Hepatic disease * HIV+ (as demonstrated by positive blood test) * Immunosuppression * Infectious related neurological injury * Other etiologies such as degenerative, mitochondrial, and metabolic disorders * Normal brain MRI * Evidence of acute illness such as fever (temperature \> 37.5 C), vomiting, diarrhea, wheezing or crackles * Progressing neurological disease (Batten Disease, Leukodystrophies, Neurotransmitter disorders) * Microcephaly, macrocephaly, cortical malformations, or genetic disorders of dysgenesis * Pulmonary disease requiring ventilator support * Unwillingness to return for follow-up visits * Contraindications to MRI

Outcomes

Primary Outcomes

Changes in Motor Performance.

GMPM (Gross Motor Performance Measure) as a standard measurement tool for assessing quality of movement.

Time frame: 6 months

Secondary Outcomes

Motor function studies

Total volumes and specific tract lesions will be studied and correlated with functional outcomes.

Time frame: 1 year

Specific white matter tract analysis using MRI

Changes on brain Diffusion Tensor Image (DTI).

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.